| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2019: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2018: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2016: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
|---|
| Outline of Final Research Achievements |
RANKL reverse signaling was known to promote osteoblast differentiation in vitro, and Wnt canonical pathway was known to promote osteoblast differentiation in vivo. However, roles of Wnt non-canonical pathways and signal crosstalk between Wnt and RANKL reverse signaling remained to be elucidated. Here, we showed that RANKL reverse signaling promotes osteoblast differentiation in vivo. RANKL has a potential as a novel pahrmacological target to enable osteoclast suppression and osteoblast activation simultaneously. We also established a method to evaluate the activation of Wnt signaling pathways quantitatively. Our finsings also suggested that the activation of Wnt/Ca pathway needs the coupling of Fzd and Ca channel at the cell surface.
|
